


Improved Overall Survival of Patients Treated with Abatacept

in Combination with Calcineurin Inhibitor (CNI) and Methotrexate (MTX) After 7/8 HLA- Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation



WHY?

Acute graft versus host disease (aGVHD) is the most common cause of early non-relapse mortality following allogeneic (cells from a donor) hematopoietic stem cell transplantation (HCT). aGVHD is caused by complex interactions between donor and recipient immune cells.


Abatacept, a drug approved to treat rheumatoid arthritis, blocks a signal that activates donor immune cells limiting their ability to cause aGVHD. A previous clinical trial (ClinicalTrials.gov: NCT01743131) reported **73.6% overall survival (OS) at 2 years** in patients who received a 7/8 human leukocyte antigen (HLA)-matched unrelated donor (7/8 MMUD) HCT following treatment with abatacept plus standard of care compared to 45.3% of matched CIBMTR controls who received standard of care alone as aGVHD prophylaxis (prevention).

The aim of this real-world analysis was to further evaluate the impact of abatacept on survival after 7/8 MMUD HCT.

WHO?

Patients ≥ 6 years of age with leukemia, lymphoma, or myelodysplastic syndrome (MDS), whose first allogeneic HCT was with a 7/8 MMUD.

The study population included 54 patients that received abatacept + standard of care GVHD prophylaxis (Aba) and 162 that received standard of care only (SOC).



PRIMARY OBJECTIVE:

Further evaluate the impact of abatacept on survival of 7/8 MMUD HCT recipients using data from the CIBMTR database of all allogeneic HCTs performed in the United States in recent years.

WHAT?


WHEN?

2011 and 2018

IMPACT / FINDINGS

This study showed that patients who were treated with Abatacept + SOC had better OS at Day 180 compared to those treated with SOC (CNI + MTX) alone (p=0.0028). Additional analyses also demonstrated improvements in overall survival when compared to SOC +ATG or SOC +post-transplant cyclophosphamide.

Research is ongoing to look at the use of abatacept to prevent GVHD. For example, consider checking out the Aba3 study: <https://pubmed.ncbi.nlm.nih.gov/33449816/>.



Learn more at [BeTheMatch.org](https://www.bethematch.org)



#BeTheMatch